Added to YB: 2025-10-02
Pitch date: 2025-09-30
CPH.TO [bullish]
Cipher Pharmaceuticals Inc.
+25.44%
current return
Author Info
Rorschach Stocks is a current NFL athlete documenting my investment portfolio and ideas. Sign up for the newsletter.
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 330.8M
Pitch Price
CAD 15.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
13.65
P/E
12.45
EV/Sales
6.52
Sector
Pharmaceuticals
Category
growth
A Real Head Scratcher... Cipher Pharmaceuticals Inc.
CPH.TO: Canadian pharma co w/ 40% insider ownership, 77% gross margins on $47.6M rev (+122% YoY). Natroba acquisition ($80M) transformational - 84% margins, 60% of rev, market share gains vs ineffective permethrin. Trading low teens FCF multiple despite runway for growth via Canada launch & int'l licensing.
Read full article (5 min)